In 2000 the availability of GHB was pronounced in New Zealand. A number of people were hospitalised with respiratory depression, high levels of sedation and coma after using GHB and precursor substances. On 1 April 2000 the media reported the first fatality from a GHB related substance in New Zealand, and this was followed by numerous admissions to hospital of patients presenting with severe respiratory depression and coma after taking these substances.